Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025HematologyOpen Access

Safety and efficacy of CD19-targeted CAR-T-cell therapy for patients with relapsed or refractory TCF3-PBX1 fusion gene-positive B-ALL

View Full Paper
Ask AI
Bookmark
Share

Authors

CHCan HuangYTYang D. TengTYTingting Yang

Discussion

Loading...

Member takes

Overview

Observational analysis shows complete remission in 4 of 7 TCF3-PBX1-positive B-ALL patients, suggesting CAR-T therapy's potential efficacy.

Key Points

  • CD19 CAR-T therapy led to complete remission in 4 out of 7 patients with TCF3-PBX1-positive B-ALL, indicating notable efficacy.
  • A median peak CD3+ T-cell expansion of 64.9% was observed in responders, with all experiencing grade 1 cytokine release syndrome.
  • Patients who achieved complete remission could either relapse or remain in sustained remission, pointing to challenges in long-term outcomes.
  • Safety assessments showed manageable adverse effects, though additional trials with larger cohorts are needed to substantiate findings.

Cite This Study

Huang et al. (2025) studied this question.

synapsesocial.com/papers/68c23b4ab210217d64784875https://doi.org/10.1080/16078454.2025.2550815
View Full Paper
Ask AI
Bookmark
Share